InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,463.54
(
0.00%
)
US TECH 100
18,611.60
(
0.30%
)
Dow Jones
40,539.93
(
0.00%
)
Brent Oil
78.46
(
-0.87%
)
Bitcoin
66,700.75
(
-0.18%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

glass_half_full

Send PM Follow Ignore
Followers 6
Posts 1203
Boards Moderated 0
Alias Born 12/09/2006

glass_half_full

Re: None

Tuesday, 06/08/2010 8:58:02 AM

Tuesday, June 08, 2010 8:58:02 AM

Post# of 80490
Hey all --

According to the new Jefferies presentation (although I'm not sure this is truly new), wrt '534 (emphasis mine):

Begin pivotal trial 2H10:
•Patients who are resistant or intolerant to either of the 2 current second-line TKIs or who have the T315I mutation
•Global study
•Regulatory path planned to parallel second-line TKIs


By second-line TKIs, I take it that Berger means disatinib and nilotinib.

If the '534 path to market is similar to those drugs, does that give us some insight?

Personally, I don't recall their approvals....
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up